ACY‐125 is an orally bioavailable HDAC6 inhibitor, currently used in clinical for treating multiple myeloma and lymphoma, exhibiting over10‐fold selectively against HDAC6 than Class I HDACs.117. Here, HDAC6 is linked to AL amyloidosis.